Physiological Regulation of Chronic Tinnitus (NeuroTin)

November 13, 2023 updated by: Wyss Center for Bio and Neuroengineering
The present project involves research on humans with the aim to characterize the reduction of chronic, continuous, non-pulsatile and debilitating tinnitus in humans by comparing neurofeedback (fMRI or EEG) to the current gold standard behavioral cognitive therapy.

Study Overview

Detailed Description

Chronic tinnitus is affecting 10-15% of people typically for many decades, with increasing prevalence with aging. Multiple therapy forms for tinnitus exist (including cognitive behavioral therapy, external white noise stimulation, meditation, and various kinds of alternative approaches), but up to now, no generally accepted successful treatment exists. Previously, it was shown that voluntary control of the activation of the auditory cortex can be learned by means of real-time functional Magnetic Resonance Imaging (fMRI) neurofeedback, and that it may alleviate tinnitus symptoms. The same seems to hold for learned increase of alpha activity localized in the auditory cortex through electroencephalography (EEG) neurofeedback. Given the high prevalence of chronic tinnitus, its significant burden for affected individuals, and given the absence of generally effective therapy, neurofeedback training for tinnitus has the potential to become a clinical application.

The main goal of this project is to comparatively assess tinnitus reduction using neurofeedback (fMRI or EEG) compared to cognitive behavioral therapy in participants with chronic severe tinnitus.

  • The participants are assigned to 3 different experimental groups (EEG neurofeedback, fMRI neurofeedback, or cognitive behavioral therapy). The participation per subject will last from 4 to 12 months.
  • The participants undergo medical tests including audiological tests as well as questionnaires related to tinnitus and quality of life at different timepoints of the study (pre and post training visits).
  • At the end of the experimental visits, each participant will have one early and one late post-assessment evaluation visits.
  • In order to evaluate the longer-term evolution of tinnitus over time, long-term follow-ups will be scheduled starting at 9 months after the final experimental visit, and will occur every 4.5 months thereafter, until research ends (for a maximum of 5 years).

Study Type

Interventional

Enrollment (Actual)

85

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • GE
      • Geneva, GE, Switzerland, 1205
        • Dept. of Otology, Audiology and Cochlear Implant Surgery, University Hospital Geneva

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age between 18 to 80 years
  2. Tinnitus Handicap Inventory ≥ 48
  3. Chronic, persistent, non-pulsatile tinnitus for minimum 6 months
  4. Functional hearing
  5. Normal inner ear structure assessment using an ear microscope, normal tympanic membrane mobility
  6. Participant willing, able and available to participate in the entire research, including completion of questionnaires and traveling to research sites for the duration of the trial

Exclusion Criteria:

  1. Contraindication to MRI (e.g. non compatible cochlear implant, pacemaker, deep brain stimulation)
  2. Conductive hearing loss exceeding 20 dB at two or more frequencies
  3. Known diagnoses causing tinnitus or hearing loss:

    • Known systemic disease (vestibular schwannoma, endolymphatic hydrops)
    • Lesion in central nervous system, including history of severe cranio-cerebral trauma
    • Acute ear canal or middle ear inflammation or effusion
  4. Significant neurologic disease, psychiatric disease, substance abuse or acute allergic disease
  5. Ongoing medication that is known to treat, influence, or cause tinnitus (e.g. high-dose aspirin, quinidine, aminoglycosides)
  6. Ongoing or recent (completed since less than 4 weeks) tinnitus therapy (e.g. tinnitus maskers, acupuncture)
  7. Participation in competitive or pharmacological study
  8. Pregnant woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: fMRI Neurofeedback
The participants receive visual feedback (displayed on a screen) related to BOLD activity from their auditory cortices, and they are asked to learn to down-regulate it.
15 intervention sessions on a 3T MRI scanner.
Experimental: EEG Neurofeedback
The participants receive visual feedback (displayed on a screen) related to the ratio of alpha to delta localized activity from their auditory cortices, and they are asked to learn to up-regulate it.
15 intervention sessions with a standard EEG-cap with 64 active electrodes.
Active Comparator: Cognitive Behavioral Therapy
Group therapy is provided by trained clinicians for research participants. Participants are confronted with tinnitus-inducting situations and trained to use diverse cognitive and behavioral coping skills to reduce the subjective impact of tinnitus burden. Such coping skills include relaxation, distraction, and de-catastrophizing, among other strategies.
10 intervention sessions of CBT group therapy, as per local university hospital standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Behavioral improvement of tinnitus as measured by the Tinnitus Handicap Inventory (THI)
Time Frame: 8 months
To show that behavioral improvement of tinnitus after intensive neurofeedback training is equivalent or better than improvement obtained after attending group cognitive behavioral therapy, as measured by Tinnitus Handicap Inventory (THI) scores reported before experiment and at late post-assessment (significant difference, p-value < 0.05). THI ranges from low scores (grade 1 - slight or no handicap), to highest scores (grade 5 - catastrophic handicap).
8 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Audiological measures
Time Frame: 8 months
If reported tinnitus scores correlate with audiological measures during research for each experimental group;
8 months
Training effect
Time Frame: 8 months
If significant behavioral change as shown by a THI grade reduction is observed before/after experiment in each group;
8 months
Other factors
Time Frame: 8 months
If there are external parameters influencing reported tinnitus levels for each group during the research, based on participant questionnaires (i.e., placebo effect of the trainer/CBT professional provider, motivation levels);
8 months
Correlation with BOLD signal
Time Frame: 8 months
Specifically for group 1 - fMRI neurofeedback, whether evolution of audiological and tinnitus measures at different research timepoints correlate with BOLD signal of the auditory cortex;
8 months
Correlation with alpha activity
Time Frame: 8 months
Specifically for group 2 - EEG neurofeedback, whether evolution of audiological and tinnitus measures at different research timepoints correlate with alpha activity of the auditory cortex;
8 months
Acceptance of intensive schedule
Time Frame: 8 months
Specifically for group 1 and 2, acceptance of neurofeedback intensive schedule of visits by participants.
8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pascal Senn, MD, PhD, Dept. of Otology, Audiology and Cochlear Implant Surgery, University Hospital Geneva

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 14, 2017

Primary Completion (Actual)

December 6, 2022

Study Completion (Actual)

March 30, 2023

Study Registration Dates

First Submitted

February 10, 2023

First Submitted That Met QC Criteria

February 10, 2023

First Posted (Actual)

February 21, 2023

Study Record Updates

Last Update Posted (Estimated)

November 14, 2023

Last Update Submitted That Met QC Criteria

November 13, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tinnitus

Clinical Trials on fMRI Neurofeedback

Subscribe